The Debtors and the last four digits of their respective taxpayer identification numbers are: Melinta Therapeutics, Inc. (0364); Cempra Pharmaceuticals, Inc. (5814); CEM-102 Pharmaceuticals, Inc. (4262); Melinta Subsidiary Corp. (9437); Rempex Pharmaceuticals, Inc. (6000); and Targanta Therapeutics Corporation (1077). The address of the Debtors’ corporate headquarters is 44 Whippany Road, Suite 280, Morristown, New Jersey 07960.

Any purchase, sale, or other transfer of equity securities in Melinta Therapeutics in violation of the procedures set forth herein (including notice requirements) shall be null and void ab initio as an act in violation of the automatic stay under Bankruptcy Code sections 362 and 105(a).

Any person or entity (as defined in Treasury Regulations section 1.382-3(a)) who currently is or becomes a Substantial Shareholder (as defined below) shall file with the Court, and serve on counsel to the Debtors (Skadden, Arps, Slate, Meagher & Flom LLP, 155 North Wacker Drive, Chicago, Illinois 60606-1720 (Attn: Ron E. Meisler, Esq. and Christopher M. Dressel, Esq.)) a notice of such status, in the form of Exhibit B-1 attached to the Final Order, on or before the later of (i) 20 calendar days after the date of this Notice and (ii) ten calendar days after becoming a Substantial Shareholder.

At least 14 calendar days prior to effectuating any transfer of equity securities (including Options to acquire such securities, as defined below) that would result in an increase in the amount of Melinta Therapeutics Stock (as defined below) beneficially owned by a Substantial Shareholder or would result in a person or entity becoming a Substantial Shareholder, such Substantial Shareholder shall file with the Court, and serve on counsel to the Debtors advance written notice, in the form of Exhibit B-2 attached to the Final Order, of the intended transfer of equity securities.

At least 14 calendar days prior to effectuating any transfer of equity securities (including Options to acquire such securities) that would result in a decrease in the amount of Melinta Therapeutics Stock beneficially owned by a Substantial Shareholder or would result in a person or entity ceasing to be a Substantial Shareholder, such Substantial Shareholder shall file with the Court, and serve on counsel to the Debtors advance written notice, in the form of Exhibit B-3 attached to the Final Order, of the intended transfer of equity securities (the notices required to be filed and served under paragraph (c) and this paragraph (d), each a “Notice of Proposed Transfer”).

The Debtors shall have 14 calendar days after receipt of a Notice of Proposed Transfer to file with the Court and serve on such Substantial Shareholder an objection to any proposed transfer of equity securities described in the Notice of Proposed Transfer on the grounds that such transfer may adversely affect the Debtors’ ability to utilize their Tax Attributes. If the Debtors file an objection, such transaction will not be effective unless approved by a final and non-appealable order of the Court. If the Debtors do not object within such 14-day period, such transaction may proceed solely as set forth in the Notice of Proposed Transfer. Further transactions within the scope of this paragraph must be the subject of additional notices as set forth herein, with an additional 14-day waiting period.

For purposes of these procedures, (i) a “Substantial Shareholder” is any person or entity (as defined in Treasury Regulations section 1.382-3(a)) which beneficially owns at least 618,781 shares of the common stock of Melinta Therapeutics (the “Melinta Therapeutics Stock”) (which amount represents 4.5% of all Melinta Therapeutics Stock issued and outstanding as of November 6, 2019), and (ii) “Beneficial Ownership” (or any variation thereof of Melinta Therapeutics Stock and Options to acquire Melinta Therapeutics Stock) shall be determined by the Debtors, in accordance with applicable rules under Section 382, Treasury Regulations promulgated thereunder, and rulings issued by the Internal Revenue Service, and thus, to the extent provided therein, from time to time shall include, without limitation, (A) direct and indirect ownership (e.g., a holding company would be considered to beneficially own all shares owned or acquired by its subsidiaries), (B) ownership by the holder’s family members and persons acting in concert with the holder to make a coordinated acquisition of stock, and (C) an Option to acquire Melinta Therapeutics Stock, but only to the extent such Option is treated as exercised under Treasury Regulation section 1.382-4(d). An “Option” is any option or right to acquire stock including, without limitation, any contingent purchase, warrant, convertible debt, put, stock subject to risk of forfeiture, contract to acquire stock, or similar interest, regardless of whether it is contingent or otherwise not currently exercisable.

Any worthless stock deduction claim of equity securities in Melinta Therapeutics in violation of the procedures set forth herein (including notice requirements) shall be null and void ab initio as an act in violation of the automatic stay under Bankruptcy Code sections 362 and 105(a).

Any person or entity (as defined in Treasury Regulations section 1.382-3(a)) who currently is or becomes a 50% Shareholder (as defined below) shall file with this Court, and serve on counsel to the Debtors a notice of such status, in the form of Exhibit B-4 attached to the Final Order, on or before the later of (i) 20 calendar days after the date of this Notice and (ii) ten calendar days after becoming a 50% Shareholder.

At least 14 days prior to filing any federal or state tax return, or any amendment to such a return, claiming any deduction for the worthlessness of the equity securities (including Options to acquire such securities, as defined below) in Melinta Therapeutics, for a tax year ending before the Debtors’ emergence from chapter 11 protection, such 50% Shareholder shall file with this Court, and serve on counsel to the Debtors advance written notice, in the form of Exhibit B-5 attached to the Final Order (a “Notice of Intent to Claim a Worthless Stock Deduction”), of the intended claim of worthlessness.

The Debtors will have 14 calendar days after receipt of a Notice of Intent to Claim a Worthless Stock Deduction to file with this Court and serve on such 50% Shareholder an objection to any proposed claim of worthlessness described in the Notice of Intent to Claim a Worthless Stock Deduction on the grounds that such claim might adversely affect the Debtors’ ability to utilize their Tax Attributes. If the Debtors file an objection, such claim will not be permitted unless approved by a final and non-appealable order of this Court. If the Debtors do not object within such 14-day period, such claim may be permitted solely as set forth in the Notice of Intent to Claim a Worthless Stock Deduction. Additional tax returns and amendments within the scope of this paragraph must be the subject of additional notices as set forth herein, with an additional 14-day waiting period.

For purposes of these procedures, (i) a “50% Shareholder” is any person or entity that at any time since December 31, 2016, has had Beneficial Ownership of 50% or more of the Melinta Therapeutics Stock, and (ii) “Beneficial Ownership” (or any variation thereof of Melinta Therapeutics Stock and Options to acquire Melinta Therapeutics Stock) shall be determined by the Debtors, in accordance with applicable rules under Section 382, Treasury Regulations promulgated thereunder, and rulings issued by the Internal Revenue Service, and thus, to the

/s/ David R. Hurst

David R. Hurst (I.D. No. 3743)

The Nemours Building

1007 North Orange Street, 4th Floor

Wilmington, Delaware 19801

Telephone: (302) 485-3900

Fax: (302) 351-8711

SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP

Joseph O. Larkin (I.D. No. 4883)

920 North King Street

Wilmington, Delaware 19801

Telephone: (302) 651-3000

Fax: (302) 651-3001

– and –

Ron E. Meisler

Albert L. Hogan III

Christopher M. Dressel

155 North Wacker Drive

Chicago, Illinois 60606-1720

Telephone: (312) 407-0700

Fax: (312) 407-0411